Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Herrington

Showing results (1-10 of 232) with videos related to

Pageof 24
Sort By:
The Canadian Journal of Cardiology|April 14, 2010
Cardiovascular genomics: outcomes and implicationsDavid M Herrington
Current Opinion in Lipidology|March 19, 2003
Role of estrogen receptor-alpha in pharmacogenetics of estrogen actionDavid M Herrington
Expert Review of Cardiovascular Therapy|January 1, 2014
Intermediate end point cardiovascular clinical trials: an excellent idea based on an obsolete paradigmJoseph Yeboah, David M Herrington
Pharmacogenomics|April 30, 2003
ER-alpha variants and the cardiovascular effects of hormone replacement therapyDavid M Herrington, Tim D Howard
Atherosclerosis|January 22, 2003
Randomized clinical trials of hormone replacement therapy for treatment or prevention of cardiovascular disease: a review of the findingsDavid M Herrington, Karen Potvin Klein
American Journal of Cardiovascular Disease|January 13, 2017
The function of cathepsins B, D, and X in atherosclerosisCaroline F Zhao, David M Herrington
Journal of Hypertension|June 9, 2005
Pharmacogenomics of blood pressure response to antihypertensive treatmentPhilip B Mellen, David M Herrington
Future Cardiology|October 7, 2009
Maintenance warfarin dose varies according to two haplotypes of the vitamin K epoxide reductase geneJerry M John, David M Herrington
Diabetes, Obesity & Metabolism|July 30, 2005
Effects of oestrogen receptor-active compounds on lipid metabolismSusan G Lakoski, David M Herrington
American Heart Journal|November 18, 2005
Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trialSusan G Lakoski, Bridget Brosnihan, David M Herrington
Pageof 24

Showing results (1-10 of 232) with videos related to

Sort By:
Pageof 24
The Canadian Journal of Cardiology|April 14, 2010
Cardiovascular genomics: outcomes and implicationsDavid M Herrington
Current Opinion in Lipidology|March 19, 2003
Role of estrogen receptor-alpha in pharmacogenetics of estrogen actionDavid M Herrington
Expert Review of Cardiovascular Therapy|January 1, 2014
Intermediate end point cardiovascular clinical trials: an excellent idea based on an obsolete paradigmJoseph Yeboah, David M Herrington
Pharmacogenomics|April 30, 2003
ER-alpha variants and the cardiovascular effects of hormone replacement therapyDavid M Herrington, Tim D Howard
Atherosclerosis|January 22, 2003
Randomized clinical trials of hormone replacement therapy for treatment or prevention of cardiovascular disease: a review of the findingsDavid M Herrington, Karen Potvin Klein
American Journal of Cardiovascular Disease|January 13, 2017
The function of cathepsins B, D, and X in atherosclerosisCaroline F Zhao, David M Herrington
Journal of Hypertension|June 9, 2005
Pharmacogenomics of blood pressure response to antihypertensive treatmentPhilip B Mellen, David M Herrington
Future Cardiology|October 7, 2009
Maintenance warfarin dose varies according to two haplotypes of the vitamin K epoxide reductase geneJerry M John, David M Herrington
Diabetes, Obesity & Metabolism|July 30, 2005
Effects of oestrogen receptor-active compounds on lipid metabolismSusan G Lakoski, David M Herrington
American Heart Journal|November 18, 2005
Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trialSusan G Lakoski, Bridget Brosnihan, David M Herrington
Pageof 24